Previous close | 0.3100 |
Open | 0.3300 |
Bid | 0.3150 x 0 |
Ask | 0.3200 x 0 |
Day's range | 0.3100 - 0.3400 |
52-week range | 0.2300 - 0.5900 |
Volume | |
Avg. volume | 87,754 |
Market cap | 26.008M |
Beta (5Y monthly) | -0.46 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0400 |
Earnings date | 11 July 2024 - 15 July 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.00 |
BROSSARD, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a second and final tranche of 3,502,931 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $980,820.68, of a non-brokered private placement initially announced on May 9, 2024 (“Private Placement”
BROSSARD, Quebec, May 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is thrilled to announce the renewal of its distribution agreement with Labtician, a leading provider of medical supplies and equipment, for the Canadian territory. This renewed distribution agreement comes after the final integration of DIAGNOS’
BROSSARD, Quebec, May 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a first tranche of 1,125,000 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $315,000, as part of a non-brokered private placement of up to 5,357,142 units, for gross proceeds of up to $1,500,0